A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 252 participants.
Also called NCT07613294
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 252 participants
- Sponsor
- Registry
-
NCT07613294 -
2025-524858-34-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia, Czechia, Hungary, Netherlands, Spain, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07613294. Randomized; double masking; primary purpose treatment. Start 2026-06-01 (actual); primary completion 2029-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
- Acronym
- ACCLAIM-CTA
- Condition
- Atherosclerosis
- Condition
- Cardiovascular Diseases
- Condition
- Lipoprotein(a)
- Intervention (Drug)
- Lepodisiran
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct07613294- Content hash
750650533fbb587011f59c3879080a7af1b11e86737ff76e99779196a18f5330